Transplant trials with Tregs: Perils and promises

Journal of Clinical Investigation

Volumn 127, Issue 7, 2017, Pages 2505-2512

  Tang, Qizhi ^a,b   Vincenti, Flavio ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL THERAPY; CLINICAL TRIAL (TOPIC); GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION TOLERANCE; IMMUNOLOGY; TRANSPLANTATION;

CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 85021744083     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI90598     Document Type: Review

References (70)

1. Sachs DH, Kawai T, Sykes M. Induction of tolerance through mixed chimerism. Cold Spring Harb Perspect Med. 2014;4(1):a015529.
2. Feng S. Spontaneous and induced tolerance for liver transplant recipients. Curr Opin Organ Transplant. 2016;21(1):53-58.
3. Spitzer TR, et al. Long-term follow-up of recipients of combined human leukocyte antigenmatched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation. 2011;91(6):672-676.
4. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med. 2013;3(11):a015552.
5. Braza F, Durand M, Degauque N, Brouard S. Regulatory T cells in kidney transplantation: new directions? Am J Transplant. 2015;15(9):2288-2300.
6. Webber AB, Vincenti F. An update on calcineurin inhibitor-free regimens: the need persists, but the landscape has changed. Transplantation. 2016;100(4):836-843.
7. Camirand G, Riella LV. Treg-centric ciew of immunosuppressive drugs in transplantation: a balancing act. Am J Transplant. 2017;17(3):601-610.
8. Furukawa A, Wisel SA, Tang Q. Impact of immune-modulatory drugs on regulatory T cell. Transplantation. 2016;100(11):2288-2300.
9. Chandran S, Feng S. Current status of tolerance in kidney transplantation. Curr Opin Nephrol Hypertens. 2016;25(6):591-601.
10. Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3+ regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol. 2011;23(6):424-430.
11. Tang Q, Bluestone J. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9(3):239-244.
12. Busse D, et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Natl Acad Sci U S A. 2010;107(7):3058-3063.
13. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852-863.
14. Cao X, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27(4):635-646.
15. Campbell DJ, Koch MA. Treg cells: patrolling a dangerous neighborhood. Nat Med. 2011;17(8):929-930.
16. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol. 2002;10(2-3):101-108.
17. Veerapathran A, Pidala J, Beato F, Yu XZ, Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood. 2011;118(20):5671-5680.
18. Zhang N, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity. 2009;30(3):458-469.
19. Jiang S, Herrera O, Lechler RI. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol. 2004;16(5):550-557.
20. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol. 2003;3(2):147-158.
21. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003;3(3):199-210.
22. Fan Z, et al. In vivo tracking of 'color-coded' effector, natural and induced regulatory T cells in the allograft response. Nat Med. 2010;16(6):718-722.
23. Raimondi G, et al. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J Immunol. 2010;184(2):624-636.
24. Lee K, Nguyen V, Lee KM, Kang SM, Tang Q. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant. 2014;14(1):27-38.
25. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009;30(5):656-665.
26. Putnam AL, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58(3):652-662.
27. Hippen KL, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41.
28. Putnam AL, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant. 2013;13(11):3010-3020.
29. Safinia N, et al. Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation. Oncotarget. 2016;7(7):7563-7577.
30. Bashuda H, et al. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest. 2005;115(7):1896-1902.
31. Ma A, et al. Adoptive transfer of CDR+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys. Int Immunopharmacol. 2011;11(5):618-629.
32. Singh K, et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant. 2014;14(12):2691-2703.
33. Zhang H, et al. Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates. Am J Transplant. 2015;15(5):1253-1266.
34. Ezzelarab MB, et al. Regulatory T cell infusion can enhance memory t cell and alloantibody responses in lymphodepleted nonhuman primate heart allograft recipients. Am J Transplant. 2016;16(7):1999-2015.
35. [No authors listed]. OPTN/SRTR 2015 Annual Data Report: Introduction. Am J Transplant. 2017;17(suppl 1):11-20.
36. Todo S, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016;64(2):632-643.
37. Chandran S, et al. Infusion of Polyclonal Tregs Modulates Subclinical Kidney Transplant Inflammation: Final Report of TASK Pilot Trial. [abstract]. Am J Transplant. 2017;17(suppl 3). http://atcmeetingabstracts.com/abstract/infusion-of-polyclonal-tregs-modulates-subclinicalkidney-transplant-inflammation-final-report-oftask-pilot-trial/. Accessed May 23, 2017.
38. Skaro A, et al. Results of a phase 1 trial of Treg adoptive cell transfer (TRACT) in de novo living donor kidney transplant recipients. [abstract]. Am J Transplant. 2016;16(suppl 3). http://atcmeetingabstracts.com/abstract/results-of-aphase-1-trial-of-treg-adoptive-cell-transfer-tractin-de-novo-living-donor-kidney-transplantrecipients/. Accessed May 23, 2017.
39. Massart A, et al. The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients. Nephrol Dial Transplant. 2016;31(6):1002-1013.
40. Hricik DE, et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol. 2015;26(12):3114-3122.
41. Vincenti F, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8(2):307-316.
42. Vincenti F. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374(26):2600-2601.
43. Matas AJ, et al. OPTN/SRTR 2013 Annual Data Report Kidney. Am J Transplant. 2015;15(suppl 2):1-34.
44. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472-484.
45. Oh-hora M, Rao A. The calcium/NFAT pathway: role in development and function of regulatory T cells. Microbes Infect. 2009;11(5):612-619.
46. Vaeth M, et al. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2012;109(40):16258-16263.
47. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33(2):153-165.
48. Haxhinasto S, Mathis D, Benoist C. The AKTmTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med. 2008;205(3):565-574.
49. Huynh A, et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol. 2015;16(2):188-196.
50. Zeng H, Yang K, Cloer C, Neale G, Vogel P, Chi H. mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature. 2013;499(7459):485-490.
51. Hanidziar D, Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr Opin Organ Transplant. 2010;15(4):411-415.
52. Kim JI, et al. Regulatory T-cell counter-regulation by innate immunity is a barrier to transplantation tolerance. Am J Transplant. 2009;9(12):2736-2744.
53. Tang Q, Lee K. Regulatory T-cell therapy for transplan tation: how many cells do we need? Curr Opin Organ Transplant. 2012;17(4):349-354.
54. Tsang JY, et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest. 2008;118(11):3619-3628.
55. Joffre O, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med. 2008;14(1):88-92.
56. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med. 2011;3(83):83ra42.
57. Wise MP, Bemelman F, Cobbold SP, Waldmann H. Linked suppression of skin graft rejection can operate through indirect recognition. J Immunol. 1998;161(11):5813-5816.
58. Ochando JC, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 2006;7(6):652-662.
59. Verginis P, McLaughlin KA, Wucherpfennig KW, von Boehmer H, Apostolou I. Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. Proc Natl Acad Sci U S A. 2008;105(9):3479-3484.
60. Porrett P, Shaked A. The failure of immunosuppression withdrawal: patient benefit is not detectable, inducible, or reproducible. Liver Transpl. 2011;17(suppl 3):S66-S68.
61. Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760.
62. Gloor JM, et al. Subclinical rejection in tacrolimustreated renal transplant recipients. Transplantation. 2002;73(12):1965-1968.
63. Moreso F, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant. 2006;6(4):747-752.
64. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant. 2005;5(10):2464-2472.
65. Flores-Mendoza A, et al. The treatment of borderline lesion in protocol biopsies did not improve the outcome in kidney transplant recipients. Am J Transplant. 2016;16(suppl 3). http://atcmeetingabstracts.com/abstract/thetreatment-of-borderline-lesion-in-protocol-biopsies-did-not-improve-the-outcome-in-kidneytransplant-recipients/. Accessed June 2, 2017.
66. Kendal A, et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med. 2011;208(10):2043-2053.
67. Young JS, et al. Erosion of transplantation tolerance after infection. Am J Transplant. 2017;17(1):81-90.
68. MacDonald KG, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126(4):1413-1424.
69. Boardman DA, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am J Transplant. 2017;17(4):931-943.
70. Noyan F, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am J Transplant. 2017;17(4):917-930.